Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of loxitane--loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients.

Author: MoyanoC Z

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Loxapine succinate (LOX) was found to be effective in treating chronic schizophrenia in 56% of patients, compared to 39% of patients treated with trifluoperazine. Both drugs had similar side effects, which were mostly mild.
Paper Details　
Original Abstract of the Article :
Therapeutic efficacy and safety of loxapine succinate (LOX) and trifluoperazine hydrochloride were compared by means of a controlled, double-blind study involving 49 chronic schizophrenic inpatients. The data indicated that LOX in dosages ranging from 40 - 65 mg/day, (usually administered on a b.i.d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/238810

データ提供：米国国立医学図書館（NLM）

Loxapine: A Viable Treatment for Chronic Schizophrenia

This double-blind study compared the efficacy and safety of loxapine succinate (LOX) and trifluoperazine hydrochloride (TFP) in treating chronic schizophrenia. The findings demonstrate that LOX, in appropriate dosages, exhibits significant anti-psychotic activity, comparable to TFP.

LOX's Efficacy in Managing Chronic Schizophrenia

The study shows that loxapine (LOX) effectively manages chronic schizophrenia, achieving comparable results to trifluoperazine (TFP). This demonstrates the potential of LOX as a viable treatment option for chronic schizophrenia.

Addressing the Challenges of Schizophrenia Treatment

Imagine schizophrenia as a desert mirage, distorting reality and making it difficult to navigate. Finding effective treatments for this complex condition is a significant challenge for clinicians. This study investigates the potential of loxapine (LOX) as a viable treatment option for chronic schizophrenia.

Dr.Camel's Conclusion

This study provides evidence for the efficacy and safety of loxapine (LOX) as a treatment for chronic schizophrenia. The findings suggest that LOX is a promising alternative to trifluoperazine (TFP), offering clinicians a valuable tool for managing this challenging condition.
Date :
  1. Date Completed 1975-10-21
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

238810

DOI: Digital Object Identifier

238810

Related Literature

Article Analysis
・Side Effects of loxapine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.